An observational study in Gastric Inflammation, Atrophic Gastritis and Intestinal Metaplasia, sponsored by Shandong University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Shandong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Gastric cancer (GC) is the fifth most common cancer and the fifth leading cause of cancer death worldwide, with 37% of new cases occurring in China. The Correa cascade describes the progression from normal gastric mucosa to chronic inflammation, atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia, and ultimately gastric cancer. Confocal laser endomicroscopy (CLE) enables real-time in vivo "optical biopsy" of gastrointestinal mucosa at subcellular resolution. However, CLE requires a learning curve and interpretation is subject to inter-operator variability. An AI diagnostic system has been developed by Qilu Hospital of Shandong University in collaboration with Wuxi Hisky Medical Technology Co., Ltd. to improve diagnostic performance and assist less experienced endoscopists. This large-sample, prospective, multicenter study aims to evaluate the diagnostic performance of the CLE AI diagnostic system for the whole-chain diagnosis of the gastric cancer Correa cascade, using histopathological diagnosis as the gold standard.
76 studies on the registry are indexed under Gastritis, Atrophic; 37 are open to participants now.
This study's planned enrollment of 784 is above the median of 520 across 55 observational studies indexed under Gastritis, Atrophic.
Browse Gastritis, Atrophic studies →Shandong University is the lead sponsor of 295 studies on the registry; 63 are open to participants now.
Compared within Gastritis, Atrophic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
patients planned to undergo upper gastrointestinal CLE examination
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled subjects undergo the same diagnostic pathway. Each suspicious lesion is examined sequentially with white light endoscopy (WLE), image-enhanced endoscopy (IEE), and confocal laser endomicroscopy (CelTouch® CLE). During CLE examination, the endoscopist provides an independent diagnosis followed by AI-assisted diagnosis.
Diagnostic Test: AI diagnostic system for CLE
All enrolled subjects undergo the same diagnostic pathway. Each suspicious lesion is examined sequentially with white light endoscopy (WLE), image-enhanced endoscopy (IEE), and confocal laser endomicroscopy (CelTouch® CLE). During CLE examination, the endoscopist provides an independent diagnosis followed by AI-assisted diagnosis.
Diagnostic accuracy of the CLE AI diagnostic system for the Correa cascade
Diagnostic accuracy of the CLE AI diagnostic system for diagnosing each category of lesions in the gastric cancer Correa cascade (inflammation, precancerous conditions, precancerous lesions, and cancer), using histopathological diagnosis as the gold standard
Time frame: 22 months
Diagnostic sensitivity of the CLE AI diagnostic system for the Correa cascade
Diagnostic sensitivity of the CLE AI diagnostic system for diagnosing each category of lesions in the gastric cancer Correa cascade (inflammation, precancerous conditions, precancerous lesions, and cancer), using histopathological diagnosis as the gold standard
Time frame: 22 months
Diagnostic specificity of the CLE AI diagnostic system for the Correa cascade
Diagnostic specificity of the CLE AI diagnostic system for diagnosing each category of lesions in the gastric cancer Correa cascade (inflammation, precancerous conditions, precancerous lesions, and cancer), using histopathological diagnosis as the gold standard
Time frame: 22 months
The comparison of diagnostic accuracy between AI system and endoscopists
Comparing the diagnostic accuracy of AI alone, endoscopists alone, and endoscopists using AI for lesion diagnosis, using histopathology as gold standard
Time frame: 22 months
The comparison of diagnostic sensitivity between AI system and endoscopists
Comparing the diagnostic sensitivity of AI alone, endoscopists alone, and endoscopists using AI for lesion diagnosis, using histopathology as gold standard
Time frame: 22 months
The comparison of diagnostic specificity between AI system and endoscopists
Comparing the diagnostic specificity of AI alone, endoscopists alone, and endoscopists using AI for lesion diagnosis, using histopathology as gold standard
Time frame: 22 months
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.